Key Points
An eight-day cyber outage reduced third-quarter sales by $150 million.
Management expects full-year 2026 organic revenue growth of 4%.
A restructuring program targets $500 million in savings over three years.
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Boston Scientific (NYSE:BSX) announced that a recent cyber incident and headwinds in key product lines will flatten sales and earnings growth through 2027. For long-term investors, this cyclical trough tests whether operational discipline and research investments can restore compounding growth. Three takeaways from the call explain where the business stands and what lies ahead.
1. Operational Disruption and Product Pressure Stand to Flatline 2027 Performance
An eight-day network outage slowed shipments, while share erosion in electrophysiology -- medical devices treating heart rhythm disorders -- and left atrial appendage closure procedures created broader top-line drag. Management expects these combined headwinds to cap sales and profit growth through next year.
As a result, we believe we will be challenged to grow sales and adjusted EPS in 2027 excluding our pending acquisition of Penumbra.
-- Michael F. Mahoney, Chairman and Chief Executive Officer
2. Corporate Restructuring Focuses on Efficient Spending to Support Long-Term Growth
To offset margin compression from shifting product mix and pricing pressure in China, leadership is overhauling supply chains and administrative functions. The cost-cutting initiative aims to streamline corporate layers without sacrificing essential research funding.
We expect these efforts to deliver sustained cost efficiencies, while allowing us to prioritize investments that support long-term growth.
-- Jonathan Monson, Executive Vice President and Chief Financial Officer
3. Product Pipelines and New Markets Target $25 Billion in Opportunities by 2030
Management is advancing pulsed-field ablation technologies -- a tissue-selective heart treatment -- and expanding cardiovascular platforms to rebuild commercial momentum. These investments aim to open major addressable market expansions by the end of the decade.
We have a very strong cadence of launches in 2027, 2028, and anticipate entering several new markets over the next few years that will lock $25 billion in new market opportunity by 2030.
-- Michael F. Mahoney, Chairman and Chief Executive Officer
Looking Ahead
Operational recovery is underway as inventory normalizes, and clinical trials in critical care support core franchises. Management is targeting high-unmet-need areas, such as cardiogenic shock.
This is both an area of major need and an area where we know that mechanical circulatory support can improve outcomes.
-- Dr. Ken Stein, Chief Medical Officer
Pending M&A and cost discipline provide additional levers to navigate near-term headwinds. Leadership expects platform upgrades to position the company for reaccelerated earnings growth.
I am confident that these actions will position us to stabilize Boston Scientific in 2027 and then drive improved revenue and adjusted earnings-per-share growth in 2028 and then further acceleration in 2029.
-- Jonathan Monson, Executive Vice President and Chief Financial Officer
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.